Tango Therapeutics Inc
NASDAQ:TNGX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.83
12.88
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Tango Therapeutics Inc
Tango Therapeutics Inc
Interest Income Expense
Tango Therapeutics Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
Interest Income Expense
$6.6m
|
CAGR 3-Years
356%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$948m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.4B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-15%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$598m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$990m
|
CAGR 3-Years
23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tango Therapeutics Inc
Glance View
Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 91 full-time employees. The company went IPO on 2020-09-03. The firm is engaged in the discovery and development of drugs at tumor suppressor gene loss in patients with unmet medical need. The Company’s product candidates include TNG908 and ubiquitin-specific protease 1 (USP1). Its TNG908, is a potent, selective, synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), which is designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. The MTAP-deletion occurs in all human tumors, including cancers with unmet need, such as squamous cell lung, esophageal and bladder cancer. The Company’s USP1, is a synthetic lethal that target for BRCA1-mutant breast, ovarian and prostate cancer. The USP1 treats a patient population for poly (ADP-ribose) polymerase (PARP) inhibitors that are operative against cancers with BRCA1 and BRCA2 mutations.
See Also
What is Tango Therapeutics Inc's Interest Income Expense?
Interest Income Expense
6.6m
USD
Based on the financial report for Dec 31, 2023, Tango Therapeutics Inc's Interest Income Expense amounts to 6.6m USD.
What is Tango Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
356%
Over the last year, the Interest Income Expense growth was 353%. The average annual Interest Income Expense growth rates for Tango Therapeutics Inc have been 356% over the past three years .
You don't have any saved screeners yet
